Karen Moorhouse, the CEO of the International Tennis Integrity Agency (ITIA), has explained the distinctions between the doping cases of Iga Swiatek and Simona Halep. Both tennis players had previously failed doping tests, but Swiatek avoided a lengthy suspension, unlike Halep.
“In Iga Swiatek’s case, the positive test result was attributed to the substance entering her system through medication. Consequently, we assessed her level of responsibility as limited. This is the reason she received a one-month suspension.”
“Halep’s case is more complex. The Court of Arbitration for Sport (CAS) acknowledged that her positive result stemmed from a supplement. To determine her degree of culpability, they considered the nature of the prohibited substance, which was not a medication. They also took into account the precautions Halep undertook to minimize the risk of contamination. Weighing these factors, CAS imposed a nine-month ban. All decisions by the authorities are based on the nature of the product in question and the measures taken by the player to mitigate the risk of contamination,” Moorhouse stated, as reported by Eurosport.fr.
